[사회]The controversial ‘AZ Vaccine’ vaccination for the elderly … what is the choice of our pharmaceutical authorities?

[앵커]

The announcement of the results of an expert advisory meeting of the pharmaceutical authorities on the approval of the AstraZeneca Corona 19 vaccine, which was scheduled for yesterday afternoon, including the availability of vaccination for the elderly, was postponed until today.

This is due to the availability of vaccines for the elderly, and as more and more European countries say they will not vaccinate the elderly, the concerns of our pharmaceutical authorities are growing deeper.

Reporter Choi Jae-min reports.

[기자]

Excluding the 60,000 Pfizer vaccines provided by COVAX, AstraZeneca is the only Corona 19 vaccine that has been confirmed to be introduced in the first quarter of Korea.

This month 630,000 people will be introduced and in the first semester 1.3 million people assigned by Kovacs will be introduced.

Quarantine authorities plan to administer this vaccine to medical personnel and the elderly first.

[정은경 / 질병관리청장 (지난 1일) : 요양병원·요양시설의 종사자들을 먼저 접종하는 것도 포함해서 검토를 하고 있는 상황입니다.]

However, a growing number of European countries are questioning the efficacy of the elderly, and the US Food and Drug Administration, the highest authority, has requested additional clinical trials.

Because of this, the concerns of our pharmaceutical authorities are also deepening.

In fact, the Ministry of Food and Drug Safety planned to disclose the use of the AstraZeneca vaccine to the Central Pharmacy Review Committee made up of outside experts yesterday.

However, the announcement was postponed for a day due to controversy until late at night.

Again, the biggest problem was whether older people were vaccinated.

At the verification advisory group meeting on the 31st of last month, drug authorities were recommended to grant a conditional permit.

[김상봉 / 식약처 바이오생약국장(지난 1일) : 참여대상자 중 고령자 수가 적다는 이유만으로 고령자에 대한 투여를 배제할 수 없다는 의견이었습니다.]

Following the announcement of the results of today’s meeting of the Central Committee for Pharmaceutical Affairs, the Ministry of Food and Drug Safety plans to decide on the approval of the AstraZeneca vaccine article after consulting soon with the final inspection committee.

While controversy continues, it is noteworthy whether national medical personnel and vaccination plans for the elderly likely to receive the AstraZeneca vaccine on an intensive basis in the first to second quarters of this year will be able to navigate.

This is YTN’s Jaemin Choi.

※ ‘Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]